Clinical Trial Update: Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating oral LDE225 (sonidegib) for Nevoid Basal Cell Carcinoma Syndrome (Gorlin syndrome) with basal cell carcinoma; results on efficacy, safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Gorlin Syndrome
• Nevoid Basal Cell Carcinoma Syndrome

Drugs mentioned

• Sonidegib (Sonidegib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Basal Cell Carcinoma, Gorlin Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2015-10-19